LA JOLLA, Calif.--(BUSINESS WIRE)--Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, today announced that it has obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society. Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture and sale of molecular diagnostic kits.
